Journal of Chest Surgery

The Korean Society for Thoracic and Cardiovascular Surgery (대한심장혈관흉부외과학회)
권호 표지

Surgical Analysis for Patients with Resected $N_2$ Lung Cancer

절제된$N_2$ 폐암환자의 생존율 분석

  • Published : 1993.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

Mediastinal lymph node involvement [N2 disease] is generally accepted as an important factor influencing the outcome of patients with lung cancer.The long-term survival rates of completely resected patients with N2 disease are frequently reported from 15% to 30%.To improve the management and the outcome of patients with resectable N2 disease, we analyzed the survival rates and the prognostic factors for resected N2 lung cancer. Between August 1989 and September 1993, we experienced 27 patients with N2 disease of 115 surgically treated lung cancer at the Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, Ulsan University Medical School. Of these 27 N2 disease 4 had only an exploratory thoracotomy, and 23 underwent pulmonary resection by pneumonectomy[15], bilobectomy[3], lobectomy[4] and sleeve lobectomy[1].All of resected 23 patients received postoperative adjuvant chemotherapy[3], radiotherapy[2] or combined chemo-radiotherapy[18].Complete follow-up was obtained in 23 patients and median survival was 22 months and overall 1-year and 2-year survival rates by Kaplan-Meir method were 65 % and 45 %, respectively. Survival differences according to histology, tumor location, number of positive nodal station and operative method were not significant, statistically. Conclusively, we think that in resectable N2 lung cancer, complete tumor resection and mediastinal lymph node dissection, and postoperative adjuvant therapy should be done to improve the survival.

Keywords

References

  1. Lung cancer v.1 Mediastinal adenopathy-the N₂lesion. International trends in general thoracic surgery Pearson,F.G.;DeLarue,N.C.;Eschapasse,H.
  2. Chest v.93 The prognostic significance of preoperative assessment of mediastinal lymph nodes in patients with lung cancer Ratto,G.B.;Mereu,C.;Motta,G.
  3. J Thorac Cardiovasc Surg v.91 Prospective evaluation of mediastinoscopy for assessment of carcinoma of the lung Luke,W.P.;Pearson,F.G.;Todd,T.R.J.;Patherson,G.A.;Cooper,J.D.
  4. J Thorac Cardiovasc Surg v.93 Selective preoperative evaluation for possible N₂ disease in carcinoma of the lung Backer,C.L.;Shields,T.W.;Lockhart,C.G.;Volgelzang,R.;LoCicero,J.
  5. Ann Thorac Surg v.40 The biological operability of stage Ⅲ non-small cell lung cancer Mountain,C.F.
  6. Ann Thorac Surg v.46 The importance of surgery to non-small cell carcinoma of lung with mediastinal lymph node metastasis Naruke,T.;Goya,T.;Tsuchiya,R.;Suemasu,K.
  7. Surg Clin N Am v.67 The role of surgery in N₂ lung cancer Martini,N.;Flehinger,B.J.
  8. Ann Thorac Surg v.51 Aggressive surgical intervention in N₂ non-small cell cancer of the lung Watanabe,Y.;Shimizu,J.;Oda,M.(et al.)
  9. Chest v.89 A new international staging system for lung cancer Mountain,C.F.
  10. J Thorac Cardiovasc Surg v.99 The significance of ipsilateral mediastinal lymph node metastasis(N₂: disease) in non-small cell carcinoma of the lung Shields,TW.
  11. Lung cancer v.4 no.suppl Extended radical operation for N₂ left lung cancer through median sternotomy Naruke,T.;Goya,T.;Tsuchiya,R.(et al.)
  12. Lung cancer v.4 no.suppl The incidence and the prognosis after contralateral mediastinal node involvement of the lung cancer pateints who underwent bilateral mediastinal dissection and pulmonary resection through the median sternotomy Hata,E.;Hayakawa,H.;Miyamoto(et al.)
  13. Bronchial carcinoma LeRoux,B.T.
  14. Ann Thorac Surg v.40 Role of mediastinoscopy in pre-treament staging of patients with primary lung cancer Coughlin,M.;Deslauriers,J.;Beaulieu,M.(et al.)
  15. J Thorac Cardiovase Surg v.83 Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung Pearson,F.G.;DeLaru,N.C.;Ilves,R.(et al.)
  16. J Thorac Cardiovasc Surg v.95 Should subcarinal lymph nodes be routinely examined in patients with non-small cell lung cancer? Thomas,P.H.;Piantadosi,S;Mountain,C.F.
  17. Chest v.90 Patterns of mediastinal metastases in bronchogenic carcinoma Libshitz,H.I.;Mckenna,R.J.Jr.;Mountain,C.F.
  18. Ann Thorac Surg v.54 Prognostic significance of computed tomography in resected N₂ lung cancer Cybulsky,I.J.;Lanza,L.A.;Ryan,M.B.(et al.)
  19. Ann Thorac Surg v.20 Relationship of cell type and lymph node metastases to survival after resection of bronchial carcinoma Shields,T.W.;Yu,J.;Conn,J.H.(et al.)
  20. Ann Surg v.202 A randomized comparison of the effects of adjuvant therapy on resected stages Ⅱ and Ⅲ non-small cell carcinoma of the lung Holmes,E.C.;Hill,L.D.;Gail,M.
  21. Ann Thorac Surg v.50 Role of postoperative radiation therapy in stage Ⅲ a non-small cell lung cancer Astudillo,J.;Conil,C.
  22. J Clin Oncol v.6 Lung cancer study group. The benefit of adjuvant treatment for resected locally advanced non-small cell lung cancer Lad,T.;Rubinstein,L.;Sadeghi,A.